

 AETNA BETTER HEALTH® OF FLORIDA 261 N. University Drive Plantation, FL 33324 www.AetnaBetterHealth.com/Florida	Date:	January 5, 2022
	Purpose:	Provider Bulletin: Inform providers of the Florida Perinatal Quality Collaborative (FPQC) educational opportunity.
	Subject:	Florida Perinatal Quality (FPQC) FREE Medical Education Trainings
	Products:	MMA OB
	From:	<u>Provider Relations</u>

Aetna Better Health® of Florida

Florida Perinatal Quality (FPQC) FREE Medical Education Trainings

Aetna Better Health of Florida would like to inform you that the Florida Perinatal Quality Collaborative (FPQC) is offering two free continuing medical education (CME) trainings on **Buprenorphine use in obstetrical practice**. This is a great opportunity to learn more on how to reduce rates of Neonatal Abstinence Syndrome (NAS) and improving birth outcomes for members.

The first module describes the basics of Buprenorphine treatment during pregnancy, and the second module details how to implement prescribing for Buprenorphine in your obstetrical practice. Additionally, a training webinar entitled "**Adding Buprenorphine Treatment in Obstetrical Practice: Lessons Learned**" will be held on **Tuesday, January 18th at 4:30 PM ET**, and can also help answer additional questions or concerns.

To register please visit: **<https://tipqc.org/tipqc-fpqc-training/>**

We appreciate the excellent care you provide to our members. If you have any other questions, please feel free to contact us via e-mail: **FLMedicaidProviderRelations@Aetna.com**. You can also fax us at 1-844-235-1340 or call us through our Provider Relations telephone line: 1-844-528-5815.

Thank you

Provider Relations Department
Aetna Better Health of Florida

Telephone: 1-844-528-5815

Fax: 1-844-235-1340

E-mail: **FLMedicaidProviderRelations@Aetna.com**

CONFIDENTIALITY NOTICE: This message is intended only for the user of the individual or entity to which it is addressed and may contain confidential and proprietary information. If you are not the intended recipient of the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is prohibited. If you received this communication in error, please notify the sender at the phone number above. **NOTICE TO RECIPIENT(S) OF INFORMATION:** Information disclosed to you pertaining to alcohol or drug abuse treatment is protected by federal confidentiality rules (42 CFR Part 2), which prohibit any further disclosure of this information by you without express written consent of the person to whom it pertains of as otherwise permitted by 42 CFR Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse patient